Abstract
Despite consolidation and/or maintenance chemotherapy most patients with newly diagnosed acute myelogenous leukemia relapse such that only 20-30% survive free of recurrence at five years. To evaluate the long-term effects of dose-intensive consolidation, we analysed 123 consecutive patients, age 16 to 84 (median 48 years), who received high-dose cytarabine-based consolidation chemotherapy. After a median follow-up of 88 months (range 26 to 126 months), 38 patients remain alive, with 26 in continued remission from 45 to 126+ months. Median remission duration for all eligible patients is 14 months (range 1.3 to 126 months) and actuarial leukemia-free survival at five years is 24 ± 8% Median survival from remission is 24 months (range 1.3 to 126 months) and actuarial survival from remission is 31 ± 9% Eighty-two patients (67% have relapsed with an actuarial risk of relapse of 71 ± 9% at five years. Adverse prognostic factors were age over 45 and male gender. When compared to historical controls (P = 0.02), dose-intensive consolidation produced improved leukemia-free survival for patients age
| Original language | English (US) |
|---|---|
| Pages (from-to) | 85-90 |
| Number of pages | 6 |
| Journal | Leukemia and Lymphoma |
| Volume | 15 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - 1994 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. / Schiller, Gary; Gajewski, James; Lee, Myung; Ho, Winston; Territo, Mary; Champlin, Richard.
In: Leukemia and Lymphoma, Vol. 15, No. 1-2, 1994, p. 85-90.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia
AU - Schiller, Gary
AU - Gajewski, James
AU - Lee, Myung
AU - Ho, Winston
AU - Territo, Mary
AU - Champlin, Richard
PY - 1994
Y1 - 1994
N2 - Despite consolidation and/or maintenance chemotherapy most patients with newly diagnosed acute myelogenous leukemia relapse such that only 20-30% survive free of recurrence at five years. To evaluate the long-term effects of dose-intensive consolidation, we analysed 123 consecutive patients, age 16 to 84 (median 48 years), who received high-dose cytarabine-based consolidation chemotherapy. After a median follow-up of 88 months (range 26 to 126 months), 38 patients remain alive, with 26 in continued remission from 45 to 126+ months. Median remission duration for all eligible patients is 14 months (range 1.3 to 126 months) and actuarial leukemia-free survival at five years is 24 ± 8% Median survival from remission is 24 months (range 1.3 to 126 months) and actuarial survival from remission is 31 ± 9% Eighty-two patients (67% have relapsed with an actuarial risk of relapse of 71 ± 9% at five years. Adverse prognostic factors were age over 45 and male gender. When compared to historical controls (P = 0.02), dose-intensive consolidation produced improved leukemia-free survival for patients age
AB - Despite consolidation and/or maintenance chemotherapy most patients with newly diagnosed acute myelogenous leukemia relapse such that only 20-30% survive free of recurrence at five years. To evaluate the long-term effects of dose-intensive consolidation, we analysed 123 consecutive patients, age 16 to 84 (median 48 years), who received high-dose cytarabine-based consolidation chemotherapy. After a median follow-up of 88 months (range 26 to 126 months), 38 patients remain alive, with 26 in continued remission from 45 to 126+ months. Median remission duration for all eligible patients is 14 months (range 1.3 to 126 months) and actuarial leukemia-free survival at five years is 24 ± 8% Median survival from remission is 24 months (range 1.3 to 126 months) and actuarial survival from remission is 31 ± 9% Eighty-two patients (67% have relapsed with an actuarial risk of relapse of 71 ± 9% at five years. Adverse prognostic factors were age over 45 and male gender. When compared to historical controls (P = 0.02), dose-intensive consolidation produced improved leukemia-free survival for patients age
UR - http://www.scopus.com/inward/record.url?scp=0027998875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027998875&partnerID=8YFLogxK
U2 - 10.3109/10428199409051682
DO - 10.3109/10428199409051682
M3 - Article
C2 - 7858506
AN - SCOPUS:0027998875
VL - 15
SP - 85
EP - 90
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 1-2
ER -